Neutrophil Elastase as A Potential Target in Ischemia-Reperfusion Injury.

IF 2.8 3区医学 Q2 PERIPHERAL VASCULAR DISEASE Current vascular pharmacology Pub Date : 2025-01-13 DOI:10.2174/0115701611345395241217053615

Yiqing Tan, Wei Zuo

引用次数: 0

Abstract

Neutrophil elastase (NE), a major protease in neutrophils, is important in promoting inflammation and multiple pathological processes. While NE is released abundantly in ischemiareperfusion (I/R) injury, the intricate relationship between NE and I/R injury remains unclear. We examine several aspects of how NE is involved in I/R injury. We also discuss the possibility of NE inhibitors used for abbreviating various types of I/R injury, such as myocardial infarction, based on preclinical research and clinical trials. Furthermore, we highlight the key question, the balance of NE and NE inhibitors, and propose new research directions. This review is useful for understanding the intrinsic interplay between NE and I/R injury-related diseases and expects to facilitate the development of effective NE inhibitors applied for I/R injury.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

中性粒细胞弹性酶作为缺血再灌注损伤的潜在靶点。

中性粒细胞弹性酶（Neutrophil elastase， NE）是中性粒细胞中的一种主要蛋白酶，在促进炎症和多种病理过程中起重要作用。虽然NE在缺血再灌注（I/R）损伤中大量释放，但NE与I/R损伤之间的复杂关系尚不清楚。我们研究了NE如何参与I/R损伤的几个方面。基于临床前研究和临床试验，我们还讨论了NE抑制剂用于缩短各种类型I/R损伤（如心肌梗死）的可能性。此外，我们强调了NE和NE抑制剂的平衡这一关键问题，并提出了新的研究方向。这一综述有助于了解NE与I/R损伤相关疾病之间的内在相互作用，并有望促进用于I/R损伤的有效NE抑制剂的开发。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current vascular pharmacology 医学-外周血管病

CiteScore

9.20

自引率

4.40%

发文量

审稿时长

6-12 weeks

期刊介绍： Current Vascular Pharmacology publishes clinical and research-based reviews/mini-reviews, original research articles, letters, debates, drug clinical trial studies and guest edited issues to update all those concerned with the treatment of vascular disease, bridging the gap between clinical practice and ongoing research. Vascular disease is the commonest cause of death in Westernized countries and its incidence is on the increase in developing countries. It follows that considerable research is directed at establishing effective treatment for acute vascular events. Long-term treatment has also received considerable attention (e.g. for symptomatic relief). Furthermore, effective prevention, whether primary or secondary, is backed by the findings of several landmark trials. Vascular disease is a complex field with primary care physicians and nurse practitioners as well as several specialties involved. The latter include cardiology, vascular and cardio thoracic surgery, general medicine, radiology, clinical pharmacology and neurology (stroke units).